Skip to main navigation Skip to search Skip to main content

Protease-Activated Receptor 1 and 4 Signal Inhibition Reduces Preterm Neonatal Hemorrhagic Brain Injury

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Purpose-This study examines the role of thrombin's protease-activated receptor (PAR)-1, PAR-4 in mediating cyclooxygenase-2 and mammalian target of rapamycin after germinal matrix hemorrhage. Methods-Germinal matrix hemorrhage was induced by intraparenchymal infusion of bacterial collagenase into the right ganglionic eminence of P7 rat pups. Animals were treated with PAR-1, PAR-4, cyclooxygenase-2, or mammalian target of rapamycin inhibitors by 1 hour, and ≤5 days. Results-We found increased thrombin activity 6 to 24 hours after germinal matrix hemorrhage, and PAR-1, PAR-4, inhibition normalized cyclooxygenase-2, and mammalian target of rapamycin by 72 hours. Early treatment with NS398 or rapamycin substantially improved long-term outcomes in juvenile animals. Conclusions-Suppressing early PAR signal transduction, and postnatal NS398 or rapamycin treatment, may help reduce germinal matrix hemorrhage severity in susceptible preterm infants.

Original languageEnglish
Pages (from-to)1710-1713
Number of pages4
JournalStroke
Volume46
Issue number6
DOIs
StatePublished - Jun 4 2015

ASJC Scopus Subject Areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Keywords

  • hydrocephalus
  • stroke
  • Animals, Newborn
  • Cyclooxygenase 2/metabolism
  • Anti-Inflammatory Agents, Non-Steroidal/pharmacology
  • Rats
  • Receptors, Thrombin/antagonists & inhibitors
  • Signal Transduction/drug effects
  • Receptor, PAR-1/antagonists & inhibitors
  • Sirolimus/pharmacology
  • Animals
  • Brain Injuries/drug therapy
  • Sulfonamides/pharmacology
  • Cerebral Hemorrhage/drug therapy
  • Immunosuppressive Agents/pharmacology
  • Nitrobenzenes/pharmacology

Cite this